| Layne M Reusser, MD | |
|
9350 E 35th St N, Ste 101, Wichita, KS 67226-2019 | |
| (316) 265-1308 | |
| (316) 712-9286 |
| Full Name | Layne M Reusser |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 38 Years |
| Location | 9350 E 35th St N, Wichita, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003879974 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 0421935 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kansas Heart Hospital | Wichita, KS | Hospital |
| Via Christi Hospital-wichita | Wichita, KS | Hospital |
| Pratt Regional Medical Center | Pratt, KS | Hospital |
| St Luke Hospital & Living Center | Marion, KS | Hospital |
| Kiowa District Hospital | Kiowa, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Layne M Reusser Md Pa | 0345398830 | 10 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. This event triggers a $1 million milestone payment to ImmunoGen.
New research projects commissioned by the National Institute for Health Research's Health Technology Assessment (NIHR HTA) programme will evaluate the effectiveness and cost-effectiveness of different screening tests used in diabetic eye care.
A study by global health service company Cigna Corporation (NYSE: CI) shows that individuals whose medical, behavioral and pharmacy health benefits are connected and administered by Cigna are more engaged in their health and well-being than those whose benefits are not fully integrated across medical, behavioral and pharmacy.
To reduce healthcare-associated infections (HAIs) in stand-alone or same-day surgical centers, the HHS Secretary Kathleen Sebelius today announced the availability of up to $9 million in funding from the American Recovery and Reinvestment Act (ARRA) to state survey agencies in 43 states. HAIs are infections some patients acquire when they are in a health care setting such as a hospital or outpatient clinic.
› Verified 3 days ago
| Entity Name | Ascension Via Christi Hospitals Wichita Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871589333 PECOS PAC ID: 5799696944 Enrollment ID: O20031118000404 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. This event triggers a $1 million milestone payment to ImmunoGen.
New research projects commissioned by the National Institute for Health Research's Health Technology Assessment (NIHR HTA) programme will evaluate the effectiveness and cost-effectiveness of different screening tests used in diabetic eye care.
A study by global health service company Cigna Corporation (NYSE: CI) shows that individuals whose medical, behavioral and pharmacy health benefits are connected and administered by Cigna are more engaged in their health and well-being than those whose benefits are not fully integrated across medical, behavioral and pharmacy.
To reduce healthcare-associated infections (HAIs) in stand-alone or same-day surgical centers, the HHS Secretary Kathleen Sebelius today announced the availability of up to $9 million in funding from the American Recovery and Reinvestment Act (ARRA) to state survey agencies in 43 states. HAIs are infections some patients acquire when they are in a health care setting such as a hospital or outpatient clinic.
› Verified 3 days ago
| Entity Name | Layne M Reusser Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598908402 PECOS PAC ID: 0345398830 Enrollment ID: O20090512000142 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. This event triggers a $1 million milestone payment to ImmunoGen.
New research projects commissioned by the National Institute for Health Research's Health Technology Assessment (NIHR HTA) programme will evaluate the effectiveness and cost-effectiveness of different screening tests used in diabetic eye care.
A study by global health service company Cigna Corporation (NYSE: CI) shows that individuals whose medical, behavioral and pharmacy health benefits are connected and administered by Cigna are more engaged in their health and well-being than those whose benefits are not fully integrated across medical, behavioral and pharmacy.
To reduce healthcare-associated infections (HAIs) in stand-alone or same-day surgical centers, the HHS Secretary Kathleen Sebelius today announced the availability of up to $9 million in funding from the American Recovery and Reinvestment Act (ARRA) to state survey agencies in 43 states. HAIs are infections some patients acquire when they are in a health care setting such as a hospital or outpatient clinic.
› Verified 3 days ago
| Entity Name | Hillsboro Hospital Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710525985 PECOS PAC ID: 4587090121 Enrollment ID: O20200407002361 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. This event triggers a $1 million milestone payment to ImmunoGen.
New research projects commissioned by the National Institute for Health Research's Health Technology Assessment (NIHR HTA) programme will evaluate the effectiveness and cost-effectiveness of different screening tests used in diabetic eye care.
A study by global health service company Cigna Corporation (NYSE: CI) shows that individuals whose medical, behavioral and pharmacy health benefits are connected and administered by Cigna are more engaged in their health and well-being than those whose benefits are not fully integrated across medical, behavioral and pharmacy.
To reduce healthcare-associated infections (HAIs) in stand-alone or same-day surgical centers, the HHS Secretary Kathleen Sebelius today announced the availability of up to $9 million in funding from the American Recovery and Reinvestment Act (ARRA) to state survey agencies in 43 states. HAIs are infections some patients acquire when they are in a health care setting such as a hospital or outpatient clinic.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Layne M Reusser, MD 9350 E 35th St N, Ste 101, Wichita, KS 67226-2019 Ph: (316) 265-1308 | Layne M Reusser, MD 9350 E 35th St N, Ste 101, Wichita, KS 67226-2019 Ph: (316) 265-1308 |
News Archive
ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that sanofi-aventis has initiated a Phase I clinical trial with SAR650984, an investigational antibody that targets cancer cells expressing the CD38 protein antigen. This event triggers a $1 million milestone payment to ImmunoGen.
New research projects commissioned by the National Institute for Health Research's Health Technology Assessment (NIHR HTA) programme will evaluate the effectiveness and cost-effectiveness of different screening tests used in diabetic eye care.
A study by global health service company Cigna Corporation (NYSE: CI) shows that individuals whose medical, behavioral and pharmacy health benefits are connected and administered by Cigna are more engaged in their health and well-being than those whose benefits are not fully integrated across medical, behavioral and pharmacy.
To reduce healthcare-associated infections (HAIs) in stand-alone or same-day surgical centers, the HHS Secretary Kathleen Sebelius today announced the availability of up to $9 million in funding from the American Recovery and Reinvestment Act (ARRA) to state survey agencies in 43 states. HAIs are infections some patients acquire when they are in a health care setting such as a hospital or outpatient clinic.
› Verified 3 days ago
Ahmad Qaddour, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 9300 E 29th St N, Suite 310, Wichita, KS 67226 Phone: 316-858-9000 Fax: 316-858-9005 | |
Kathryn Watkins Brickman, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 550 N Hillside St, Wichita, KS 67214 Phone: 316-962-2000 Fax: 303-306-7753 | |
Ray F Fisher, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 818 N Carriage Pkwy, Wichita, KS 67208 Phone: 316-651-2252 Fax: 316-651-2314 | |
Mitchell A Morgan, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1131 S Clifton Ave, Suite B, Wichita, KS 67218 Phone: 316-462-1040 Fax: 316-462-1042 | |
Dr. Kent B Murray, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 5500 E Kellogg Dr, Wichita, KS 67218 Phone: 316-651-3603 Fax: 316-651-6666 | |
Dr. Raghu C Chaparala, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2160 W 21st St N, Wichita, KS 67203 Phone: 316-267-7175 Fax: 316-425-7799 |